Short-term efficacy of nucleos (t)ide analogues in patients with hepatitis B virus-related chronic liver failure: a Meta-analysis
10.3760/cma.j.issn.1000-6680.2012.02.011
- VernacularTitle:核苷(酸)类似物治疗乙型肝炎病毒相关慢性肝功能衰竭患者近期疗效的Meta分析
- Author:
Ru JI
;
Caiyan ZHAO
- Publication Type:Journal Article
- Keywords:
Nucleosides;
Hepatitis B virus;
Liver failure;
Meta-analysis
- From:
Chinese Journal of Infectious Diseases
2012;30(2):105-112
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of nucleos(t)ide analogues in patients with hepatitis B virus(HBV)-related chronic liver failure through Meta-analysis.Methods Literature search was done in Medline, PubMed, China National Knowledge Infrastracture(CNKI), Wanfang Database and China Biology Medicine(CBM)for papers published from 1990 to 2010 in Chinese or English, as well as the references in the relevant literature complemented by retrospective and manual literature search. Only literatures fully matching the inclusion and exclusion criteria could be included in this study. RavMan 5.0 statistical software was utilized for Meta-analysis. Then the sensitivity and publication bias about the data were measured by forest pl0t, funnel plot and fail-safe number. Results Total 1240 patients from 20 controlled clinical trials reported in Chinese and English papers were included in this study. The indicators of therapeutic efficacy were as below: HBV DNA undetectable rate relative risk(RR)=3. 37, 95％CI: 2. 20, 5. 16(Z=5. 60, P＜0. 01), prothrombin activity(PTA)weighted mean difference(WMD)=34.70, 95％CI: 25.62, 43.79(Z=7.49, P＜0.01), albumin(Alb)WMD=4.73, 95％ CI: 2.95, 6.51(Z=5.21, P＜0.01), alanine aminotransferase(ALT)WMD=42.58, 95％CI: -59.74, -25.41(Z=4.86, P＜0.01), total bilirubin(Tbil)WMD=-150.95, 95％CI: -199.29,-102.62(Z=6.12, P＜0.01), mortality RR=0. 55, 95％ CI: 0. 48, 0. 64(Z=8. 09, P＜0. 01). Conclusion Nucleos(t)ide analogues treatment could significantly increase HBV DNA undetectable rate, improve PTA and Alb, decrease levels of ALT and Tbil, which further reduces the short-term mortality of the patients with HBV-related chronic liver failure.
